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Abstract
Background: Histone acetylation is an epigenetic modification involved in the regulation of gene
expression, balanced by histone acetyl transferases and histone deacetylase (HDAC) enzymes.
HDAC inhibitors (HDACi) induce growth arrest and cell death in transformed cells, and are
currently in many clinical cancer trials. The transcriptional response to HDACi is complex, as is the
response to HDAC isoform knockdown (KD). Here, we describe for the first time in a human
cancer cell line, a transcriptional comparison of treatment by two structurally unrelated HDACi;
belinostat and valproic acid with the KD of HDAC1, 2 and 3 isoforms.
Results: HDAC KD showed anti-proliferative effects, although to a lesser extent than HDACi
treatment. Moreover, we found a 2-fold increased resistance of HDAC1 knockdown cells to
belinostat, suggesting this isoenzyme as a selective target. While both HDACi treatment and
individual class I HDAC KD produce significant transcriptional effects, three-times higher for
HDACi, the gene-expression profiles of class I HDAC KD compared with that obtained by HDACi
treatment exhibited less than 4% of altered genes in common between the two modes of inhibition.
Further, cell-specific effects of HDAC KD are evident by comparison with a recent study in a
different cell line.
Conclusion: The increased resistance to belinostat in response to HDAC1 depletion indicates the
possibility of using this isoform as a predictive biomarker of response to HDACi treatment.
Further, the transcriptional response to chemical inhibition of HDACs is very different from that
of KD of individual class I HDAC isoforms. These data suggest that the anti-tumor effect of HDACi
is indeed linked to class I inhibition, but may be more complex than simply targeting individual
HDAC enzymes.
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Background
The transcription of genes is highly regulated by epige-
netic chromatin modifications, including the acetylation
of lysine residues protruding from nucleosomal histones.
Thus, histone acetylation status is maintained by the
opposing actions of histone acetyl transferase and histone
deacetylase (HDAC) enzymes [1,2]. HDACs modify gene
expression via multiple mechanisms. The deacetylation of
histones causes general chromosome condensation, and
also plays a role in transcriptional regulation by forming
a combinatorial 'histone code' that regulates downstream
responses [2,3]. Additionally, a variety of non-histone tar-
gets such as transcription factors, structural and chaper-
one proteins are targeted by HDAC enzymes [4]. The
Zn2+-dependent mammalian HDAC isoenzymes are
divided into three classes based on their homology to
yeast deacetylase proteins. Class I HDAC isoforms include
HDAC1, -2 and -3 that are ubiquitously expressed as well
as the low-abundance HDAC8. Class II (HDAC4, 5, 6, 7,
9, 10) and IV (HDAC11) isoforms display a more
restricted tissue pattern of expression [1]. A number of
cofactors are required for HDAC activity; indeed, they
reside in multi-protein complexes including co-regulators
and other chromatin-modifying enzymes [2].
Recent advances into the biology of HDAC enzymes
reveal a substantial division of labor between HDAC sub-
types [2,5]. Modulating HDAC expression demonstrates
that class I HDACs are essential for proliferation and sur-
vival. Hence, HDAC1 and HDAC3 are believed to be
important for proliferation [6-9], whereas HDAC2 is
likely involved in the regulation of apoptosis [10,11].
HDAC8 has been implicated in smooth muscle cell con-
tractility [12], though its knockdown (KD) also affects
proliferation in tumor cells [13]. Class II HDACs are
mainly involved in cell differentiation and development
[14], while selective HDAC6 inhibition by tubacin also
induced cytotoxicity without accompanying gene-expres-
sion changes [15]. Aberrant expression of HDAC1, 2, 3
and 6 has been observed in various tumor types [16-21],
and HDAC2-mutant mice display reduced tumor devel-
opment [22]. Further, the transformed epigenome of neo-
plastic cells includes specific hypo-acetylation of histone
H4 [23]. Together, these findings provide the rationale for
the targeted inhibition of HDAC enzymes. HDACi treat-
ment increases global acetylation levels, which ultimately
results in cell cycle arrest, apoptosis or terminal differenti-
ation of transformed cells. A considerable variation in the
gene-expression response to HDACi depending on cell
line and structural class of drug has been demonstrated,
and because HDACi treatment potentially affects the
entire transcriptome, it is interesting that pan-HDAC inhi-
bition changes the expression of a relatively small percent-
age of genes [24,25]. There are several structurally distinct
HDACi currently in clinical trials for the treatment of solid
and hematological cancers, of which the hydroxamate
Zolinza (vorinostat, SAHA), recently gained approval for
the treatment of cutaneous T-cell lymphoma [26].
Despite several reports on the effects of HDAC KD in
human and other species, a direct comparison of global
gene-expression changes between individual class I HDAC
KD and HDACi treatment has not previously been per-
formed on human cancer cell lines. In this report, we
examined viability parameters and transcriptional profiles
of human HDAC1, 2 and 3 KD, and directly compared
expression profiles with treatment of near-IC50 doses of
two structurally distinct HDACi; the pan-inhibitory
hydroxamate belinostat (PXD101) and the class I selective
short-chain fatty acid valproic acid (VPA) [26]. Further, we
compared HeLa class I HDAC KD microarray data with
that obtained in a recent similar study on U2OS cells.
Results
Depletion of HDAC1, 2 and 3 affect viability
Efficient and specific down-regulation of HDAC1, -2 and
-3 was obtained in HeLa cells at both protein (Fig. 1A) and
mRNA levels (Table 1, bold), by using the siRNA technol-
ogy. Viability, as measured by metabolically active cells
present in culture, was consistently reduced by 20, 23 and
16% following HDAC1, -2 and -3 KD, respectively (Fig.
1B). A similar effect was seen in HCT116 and MCF-7 cells
(data not shown). In HDAC1+2 double KD cells, prolifer-
ation was reduced by 35% and 25% when compared with
single HDAC1 KD and HDAC2 KD cells, respectively (see
additional file 4). Apoptotic effector caspase-3/7 activity
was significantly increased for HDAC1, -2 and combina-
tion KD (1.65-, 1.45- and 1.63-fold respectively, p < 0.01),
but not for HDAC3 KD alone. Further, a dose-response of
1.4, 1.8 and 2.3-fold increased apoptosis at 0.1, 1.0 and
10.0 μM at 24 hours is evident for belinostat treatment
(Fig. 1C). No indication of cell cycle deregulation was
observed for class I HDAC KD in HeLa at 48 hours post-
transfection. However, an increase in the subdiploid pop-
ulation corresponding to fragmented cells was observed
for especially HDAC2 and to some extent in HDAC3 KD
cells, though not for HDAC1 KD cells. In comparison,
belinostat treatment showed marked cell cycle alterations
and cell debris (Fig. 1D).
HDAC1 knockdown reduces sensitivity to the HDACi 
belinostat
Next, we examined how HeLa cells respond to HDACi
treatment following individual class I HDAC enzyme
down-regulation (Fig. 2). Interestingly, HDAC1 KD signif-
icantly increased IC50 values almost 2-fold towards the
hydroxamate belinostat (p < 0.01), which was not seen in
response to either HDAC2 or 3 depletion. When examin-
ing VPA, no significance was observed for either HDAC
KD condition.Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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Effects of HDAC depletion by siRNA in HeLa cells Figure 1
Effects of HDAC depletion by siRNA in HeLa cells. A) Down-regulation of HDAC1, 2 or 3 protein after treatment with 
HDAC1, 2 or 3-targeted siRNA respectively, alone or in combination with other siRNAs at 72 hours post-transfection. Top-
row is the appropriate antibody (HDAC1, 2 or 3), while the bottom-row is loading control actin; B) viability as measured by 
ATP present in culture. For each HDAC knockdown condition, viability was consistently reduced as compared to scrambled 
siRNA control, in independent measurements (p < 0.01, n = 24); C) The activity of effector caspases 3 and 7 corresponding to 
apoptotic progression upon HDAC down-regulation or belinostat treatment at increasing concentrations for 24 hours for 
comparison; D) flow cytometric analysis of DNA content as a function of cell number in control or HDAC combination KD at 
48 hours post-transfection, or belinostat treatment at 5.0 μM for 24 hours.Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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Gene-expression profiles of belinostat and VPA treatment
Global gene-expression analysis has previously been per-
formed following HDACi treatment regimens primarily in
human cell lines [24,25], but only once recently for indi-
vidual human class I HDAC KD [9]. However, a direct
comparison of gene-expression profiles for each has not
been reported. To determine first the transcriptional
responses to the HDACi used, DNA chip analyses were
Table 1: Examples of gene-expression changes in response to HDACi treatment or single class I HDAC enzyme depletion.
Gene symbol Gene name Probe nr. Belinostat Valproic acid HDAC1 KD HDAC2 KD HDAC3 KD
Transcription
HDAC1 Histone deacetylase 1 201209_at 0.10
HDAC2 Histone deacetylase 2 201833_at 0.10
HDAC3 Histone deacetylase 3 216326_s_at 0.14
JUN Jun oncogene (AP-1) 201465_s_at 0.38 0.41 0.42
SMAD3 SMAD family member 3 218284_at 0.53 0.49 0.55
RAF1 v-raf-1 murine leukemia viral oncogene 
homolog
201244_s_at 2.88 2.94 2.93
Metabolism
CTPS CTP synthase 202613_at 0.39 0.44
TYMS Thymidylate synthase 202589_at 0.62 0.43
FUCA Fucosidase, alpha-L-1, tissue 202838_at 5.86 5.41
SAT1 Spermidine/spermine N1-
acetyltransferase 1
210592_s_at 3.81 3.54
Cell cycle
CDKN1A Cyclin-dependent kinase inhibitor 1A 
(p21, Cip1)
202284_s_at 4.15 3.16
CDC25B Cell division cycle 25 homolog B 201853_s_at 0.68 0.58
HRASLS3 HRAS-like suppressor 3 209581_at 5.96 4.70 4.14 2.31 2.11
CCNB1 Cyclin B1 214710_s_at 0.55 0.39
CCND1 Cyclin D1 208712_at 0.38
CCND2 Cyclin D2 200951_s_at 2.29
CCNE1 Cyclin E1 213523_at 2.04 1.69
CCNG1 Cyclin G1 208796_s_at 4.39 4.11 3.31
Apoptosis
FAIM Fas apoptotic inhibitory molecule 220643_s_at 0.32 0.17
BCL2L11 BCL2-like 11 (apoptosis facilitator) 
(BIM)
1555372_at 1.95
CASP3 Caspase 3 202763_at 0.51 0.52
CASP7 Caspase 7 207181_s_at 1.86 1.72 1.53
CASP9 Caspase 9 203984_s_at 1.57 3.24 1.87
FAS FAS 
(TNF receptor superfamily, member 6)
216252_x_at 1.55 0.65
Cell signaling
RASGRP2 RAS guanyl releasing protein 2 214369_s_at 3.16 6.06
MYC v-myc myelocytomatosis viral oncogene 
homolog
202431_s_at 0.43
MINA MYC induced nuclear antigen 213189_at 0.31 0.40
TGFα Transforming growth factor, alpha 205016_at 3.24
RASGRP1 RAS guanyl releasing protein 1 205590_at 0.12 0.10 0.25
CGA glycoprotein hormones, alpha 
polypeptide
204637_at 5.30 4.36 2.66 16.53 6.27
Miscellaneous
KPNB1 Importin β 208975_s_at 0.67 0.57
SERPINE1 Serpin peptidase inhibitor, clade E 202627_s_at 0.21 0.23 0.22
EDN1 Endothelin 1 218995_s_at 0.45 0.45 0.45
THBS1 Thrombospondin 1 201108_s_at 0.30 0.30 0.51
ADAM19 ADAM metallopeptidase domain 19 209765_at 0.33 0.37
PDK4 Pyruvate dehydrogenase kinase 4 205960_at 4.13 7.34 2.74 3.31 4.38
ATP10D ATPase, Class V, type 10D 213238_at 3.85 3.46 2.40 2.04 2.88
Absolute fold-changes related to untreated or scrambled control for HDACi (VPA or belinostat) or HDAC 1, 2, or 3 KD samples respectively are 
listed. Blank fields correspond to no significant changes above 1.5-fold. The complete gene list of all genes regulated by 2-fold or more is accessible 
as supplementary material (Table A).Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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Mean HDACi IC50 values of mock treated or HDAC deprived HeLa cells Figure 2
Mean HDACi IC50 values of mock treated or HDAC deprived HeLa cells. HDAC1 KD significantly increases the 
resistance to belinostat on average 1.9-fold (p < 0.01, n = 10), which is not observed for HDAC2 or -3 KD cells. For VPA, no 
significance was obtained for the 1.4-fold-changes seen in response to both HDAC1 and -3 KD (n = 5). For all figures, standard 
errors of the mean IC50 value for each condition are shown. The chemical structures for belinostat and VPA are shown over 
the graphs.
Significant differentially expressed transcripts Figure 3
Significant differentially expressed transcripts. Found by statistical Limma analysis for each treatment condition vs. their 
respective control, with an arbitrary 2.0-fold cut-off value. Gene redundancy was taken into account, which left 26902 probes 
from the chip as total number of genes. The total number of regulated genes, and the proportion of genes up- or down-regu-
lated are shown.Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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performed in independent triplicates for each condition;
mock treated control, belinostat and VPA treatment in
HeLa cells (0.5 μM and 3.0 mM respectively for 24 hours).
The doses chosen were close to the IC50 values in HeLa:
0.76 μM and 3.3 mM for belinostat and VPA respectively,
and induced histone H3 and H4 hyper-acetylation (data
not shown). Differential gene-expression patterns were
detected between each experimental condition versus
control. Fig. 3 summarizes the number of non-redundant
genes significantly deregulated in response to drug treat-
ment, at an arbitrary 2.0 fold-change cut-off value. The
number of genes deregulated by belinostat or VPA is 5.3
and 6.0% respectively. Further, a greater proportion of
genes are induced by both drugs (63 and 66% respec-
tively). The relationship of differentially expressed genes
between belinostat and VPA was illustrated by Venn dia-
grams (Fig. 4), and demonstrated that approximately 30%
of altered genes responded identically between drug treat-
ments.
In the literature, certain genes have been identified whose
expression is affected by HDACi treatment [24,25]. For
instance, Glaser et al. recognized a common set of 13 core
genes whose expression were universally altered in
response to various HDACi in multiple cell types [24].
Some of the commonly affected genes are listed in Table
1 for belinostat and VPA treatment, and these include up-
regulation of CDKN1A (p21) and FUCA and down-regu-
lation of TYMS, CTPS and KPNB1 (importin β) by both
drugs. Hence, this study confirms a subset of 5 of the 13
core genes besides other known HDACi target genes.
Comprehensive gene-lists of all conditions at above 2-
fold changes are accessible (see additional file 2). Data
were validated by qRT-PCR analysis on 9 selected genes
on RNA samples used in microarray analysis plus inde-
pendent ones, and an overall good correlation to the
microarray data was observed (see additional file 1).
Overlapping genes between conditions Figure 4
Overlapping genes between conditions. Venn diagrams illustrating the distribution of significantly regulated transcripts 
between each of the 5 conditions, including non-redundant genes at ≥ 2.0-fold expression changes. Up-regulated genes are 
shown in green, down-regulated in red. The numbers between two conditions illustrate the number of genes regulated in the 
same direction in both conditions.Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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Gene-expression profiles of class I HDAC depletion
Further, we conducted a genome-wide analysis of the tran-
scriptional response to siRNA-mediated depletion of three
class I HDACs in HeLa cells. As for HDACi samples, DNA
chip analyses were carried out in independent triplicates
for each condition; scrambled siRNA control, HDAC1, -2
and -3 KD at 48 hours post-transfection. Differential gene-
expression patterns between each knockdown condition
and scrambled control were identified by statistical analy-
sis. Efficient KD was confirmed by the microarray data, as
each HDAC isoform was specifically down-regulated 7–
10 fold (Table 1, bold). The proportion of non-redundant
significant transcripts affected by the down-regulation of
each HDAC enzyme at 2.0-fold change or more is in the
range 1.4–2.0% (shown in Fig. 3), and highest for HDAC1
KD. As for HDACi drugs, a slight overweight of transcripts
was induced for HDAC1 and -2 KD samples. In contrast,
HDAC3 KD was the only condition not showing this pat-
tern. The proportion of genes with identical expression
between KD conditions was in the order of 19–27% (Fig.
4), with HDAC1 KD displaying the least overlap with the
other two KD conditions. Further, the individual HDAC
isoenzyme targeted by its specific siRNA was the most
down-regulated gene in each respective sample, and
siRNA targeting one HDAC did not affect expression levels
of other class I HDACs. The complete gene lists for all con-
ditions ≥ 2.0-fold changes are accessible (see additional
file 2). Also, data were validated by qRT-PCR analysis on
6 selected genes on RNA samples used in microarray anal-
ysis plus independent ones, which overall had good cor-
relations to the microarray data (see additional file 1). We
further addressed the effect of a combined HDAC1+2 KD
by analyzing mRNA expression of three genes (HRASLS3,
CCND1 and THBS) found to be affected by each individ-
ual HDAC KD. For the CCND1 and THBS genes, KD of
either HDAC1 or -2 reduced expression by approximately
50–75% compared to control; an effect not observed in
double HDAC1+2 KD (Supplemental figure 2B). For the
expression of the HRASLS3 gene, an increase of approxi-
mately 50% is seen with single HDAC1 or -2 KD, which
increases to approximately 200% in HDAC1+2 double
KD cells. Together, these data indicate a degree of redun-
dancy of the HDAC1 and -2 proteins.
Cell-specific effects of individual class I HDAC depletion
A previous report by Senese et al. [9] studied the transcrip-
tional effect of HDAC1, 2 and 3 KD in the human U2OS
osteosarcoma cell line, by microarray analysis. In a direct
comparison study, we find very little overlap between the
results obtained in the present study and the data recently
published by Senese et al. [9]. As discussed below, this
apparent discrepancy can be attributed to both methodo-
logical and biological differences between the two studies.
First, while the experimental design in the Senese study
relies on 2 technical replicates of a biological pool on each
array, which is then scanned twice (before and after
amplification), in our study, we have chosen the more tra-
ditional approach with 3 independent biological repli-
cates for each experimental condition and array. Because
the biological variation between individual samples most
often is much larger than the assay variation [41], it
appears more efficient to perform single arrays on inde-
pendent biological samples, rather than replicate arrays
on a limited number of samples.
Second, we had the opportunity to reanalyze the data
(CEL files kindly provided by Dr. Susanna Chiocca, Euro-
pean Institute of Oncology, Milan, Italy) from the Senese
study. In our hands, the number of significantly regulated
genes following HDAC siRNA inhibition is much lower
than reported in the original study (Additional file 5, slide
19). This disparity is probably due to the stringent filter-
ing criteria applied in our analysis, where we require the
absolute difference between differentially expressed genes
to be 50 or more, as otherwise, the risk of obtaining false
positive results due to genes that are close to the back-
ground level, is high. Finally, we have made a direct com-
parison between our knockdown experiments and those
performed by Senese et al. From this analysis, it is evident
that the overriding differences observed between the two
studies are due to cell type specific effects. Both the PCA
plot based on 1965 probes that vary between experimen-
tal conditions (Additional file5 , slide 29) and the unsu-
pervised hierarchical clustering (Additional file 5, slide
30) imply that the two data sets are clearly separated, and
only have a few genes in common when looking at each
specific HDAC. That it is indeed the biology that is the
main variable between the two studies, and not a techni-
cal artifact, is supported by looking at the expression lev-
els of the three HDACs, which are all among the most
down-regulated genes, when their corresponding siRNA is
transfected into the cells. Thus, we do see HDAC specific
effects common for the two studies, but the predominant
effects are due to the diverse biology of the two systems.
Interestingly, HDAC3 is only number 122 among the
most down-regulated genes in the HDAC3 siRNA experi-
ment in the Senese et al. paper. This can be explained by
the already low HDAC3 expression in the control cells, so
going from a low basal expression to a lower siRNA inhib-
ited expression level will not give as large a fold-change as
when looking at a gene with a high basal expression. In
summary, the low degree of concordance between the two
studies can be attributed mainly to cell specific differ-
ences, which further emphasizes the importance and
impact of the model system chosen for a particular study
(see additonal file 6).Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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Dissimilar transcriptional profiles between individual 
HDAC depletion and HDACi treatment
We thus wanted to directly compare individual class I
HDAC enzyme knockdown with the treatment of two
structurally distinct classes of HDACi in the same cell line,
as this has not been done previously in human cells.
Approximately three times more genes are deregulated by
enzymatic HDACi treatment than by individual class I
HDAC depletion (Fig. 3). Between treatment types, a
slightly greater proportion of genes are in common for the
two structurally distinct HDACi, than are in common for
KD of individual HDACs from the same class. However,
the biggest difference occurs when comparing single class
I HDAC KD with HDACi treatment, as merely 1.6–3.4%
of altered genes overlap between these conditions,
depending on enzyme and drug assayed (Fig. 4). Thus,
only a small proportion of genes respond identically
when either knocking down single class I HDAC enzymes
or inhibiting multiple HDACs enzymatically. A complete
list of genes whose expression is altered in the same direc-
tion between one or more HDAC KDs and one or both
HDACi treatments are listed (see additional file 3),
including genes with ≥ 2.0-fold changes only. This com-
prises merely 109 genes altered in response to both types
of HDAC inhibition, and includes genes involved in proc-
esses such as transcriptional regulation, gametogenesis
and development, metabolism and intracellular traffick-
ing. Of the 109 genes, 7 are up-regulated simultaneously
in all 5 conditions; 3 with unknown function besides
HRASLS3 involved in negative cell cycle regulation, CGA
involved in cell-cell signaling, PDK4 involved in carbohy-
drate metabolism and the ion transporter ATP10D.
Discussion
Targeting cancer through epigenetic control mechanisms
is an area of growing interest. While HDACi show promise
in clinical trials, the contribution of each HDAC isoen-
zyme in the anti-proliferative response of HDACi is
unknown. In the present study, we directly compared
gene-expression profiles between the two modes of
HDAC inhibition; single class I HDAC protein depletion
by siRNA and enzymatic HDACi treatment in a human
cancer cell line. It is recognized, that HDACs function in
multi-protein complexes and their depletion therefore
might have a dissimilar outcome to HDACi treatment
[27], however this has not been directly addressed previ-
ously.
The reduced viability that we observe upon individual
HDAC1, -2 and -3 knockdown has been published on
class I HDAC KD in cancer cells, especially via prolifera-
tion for HDAC1 and -3, and via apoptosis for HDAC2
[6,8,11,19]. We also detected an increased subdiploid
population of HDAC2 and less for -3 KD cells, whereas
caspase activity was increased for HDAC1 and -2 KD cells.
Thus, mediators of apoptosis following HDAC KD might
be dissimilar between the isoforms examined. Caspase 3
as a mediator of apoptosis in HDAC1 KD cells was
recently reported [9], as was an increased subdiploid pop-
ulation for HDAC2 KD [10,19] and HDAC3 KD [6,19,28],
but not in HDAC1 KD [19], thus supporting our results.
Further, we found no major alterations in cell cycle distri-
bution in response to class I HDAC KD, which is in agree-
ment with other reports [10,11,28]. To conclude, class I
HDAC KD causes a reduction in viability and an increase
in apoptosis, however at much lower levels than detected
for HDACi treatment, as this is not transferred to altera-
tions in cell cycle distributions.
Published data suggest a wide range in the proportion of
genes deregulated in response to HDACi treatment;
between 1–22%. This depends on factors such as class of
compound, dosage, incubation time and choice of cell
line [24,25,29-31]. Hence, our data on belinostat and VPA
in HeLa cells are within this broad range. Between belino-
stat and VPA, the shared proportion of genes of 30% prob-
ably correspond to the overlapping functions as HDAC
inhibitors as both drugs affect some typical HDACi-
induced genes, whereas differences are attributed to struc-
tural dissimilarities, HDAC class specificity, and non-
HDACi functions of VPA. Other reports comparing the
transcriptional response of different HDACi compounds
find approximately 45% similarities between trichostatin
A (TSA) and either tributyrate or vorinostat and 77% iden-
tical genes between tributyrate and vorinostat treatment,
when examining three cancer cell lines [25], while vorino-
stat and depsipeptide had very similar responses in one
cell line, especially in the first hours of treatment [31].
Further, of the limited 'core' set of 13 genes universally
affected by HDACi treatment [24], 5 were reproduced by
both drugs in this study. In response to single class I
HDAC down-regulation, none of these 13 genes were
altered, however the expression of a considerable amount
of genes were altered that included genes involved in pro-
liferation, apoptosis or adhesion. For HDAC1, this corre-
sponds to data on C. elegans in which 2.2% were altered
by ≥ 1.8-fold [32], albeit lower than the 7% observed in
HDAC1 knockout of untransformed murine embryonic
stem cells at 2-fold or more [33], probably due to the com-
plete abrogation of HDAC1 in this system. HDACi treat-
ment and individual HDAC KD have been shown to cause
both up- and down-regulation of multiple gene targets
[5,32,33]. The knockdown of class I HDAC enzymes in
this report showed that near equal proportions of genes
were induced as were repressed by HDAC KD, with a
slight overweight of induced genes for HDAC1 and -2 KD
and a slight overweight of down-regulated genes for
HDAC3, possibly separating this isoform as mainly a tran-
scriptional activator. As HDAC1 and -2 reside in the same
co-repressor complexes, the disruption of these mightMolecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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have more similar outcomes. Moreover, we found that
HDAC1 KD altered the greatest number of genes, and
hence might affect gene transcription to a larger extent
than HDAC2 and -3. Between the three KD conditions, we
found most genes (73–80%) to be uniquely deregulated
upon individual HDAC KD, with HDAC1 having the least
degree of overlap. This suggests distinctive transcriptional
targets for HDAC enzymes from the same class, and could
thus provide the basis for discrete functions between class
I HDACs [11]. In comparison with genes affected by
HDAC1, -2 or -3 KD by siRNA in human U2OS cells in a
recent study [9], the majority were not reproduced herein,
and generally point to cell-line specific responses to
HDAC depletion. This emphasizes the importance of
comparing HDAC KD with HDACi treatment in the same
cell line.
Finally, we compared individual KD of class I HDAC
members with two dissimilar HDACi compounds at near-
IC50 doses. At the treatment regimens chosen, three times
more genes were deregulated by HDACi treatment than by
individual class I HDAC KD. As these drugs target multi-
ple HDACs, this is not unexpected. The overlap of genes
between HDACi treatments and between individual
HDAC KD was in a similar range; 20–30%. When looking
into the genes whose expression overlapped between
HDACi treatment and individual KD of the target HDACs
of these compounds, a surprisingly low degree of similar-
ity was observed, namely less than 4% of regulated genes.
The reason for the low degree of overlap could have sev-
eral explanations. First, some degree of redundancy might
occur after individual HDAC KD. A prior study in Dro-
sophila showed an overlapping proportion of 20% (469
of 2347 genes regulated in total) between DHDAC1 KD
and TSA treatment, each for 5 days post-treatment. How-
ever, reducing TSA treatment to 6 hours also reduced the
overlap to 4.5% (52/1151), thus differences in experi-
mental set-up probably account for a large variation in
these numbers. For DHDAC3 KD, the overlap with TSA
treatment was 2%, and the authors conclude that espe-
cially DHDAC1 affected gene expression in a similar man-
ner to TSA [34]. The closer resemblance between
DHDAC1 and TSA profiles might be because Drosophila
has fewer HDAC enzymes and DHDAC1 is orthologous to
both human HDAC1 and -2. Second, depleting HDAC
levels most likely interferes with the multi-protein com-
plexes in which they reside in a different manner than by
enzymatic drug inhibition of HDAC, causing differential
cellular responses. It has previously been shown in Dro-
sophila, that DHDAC1 deficiency and point mutations
had dissimilar phenotypic outcomes, the latter presuma-
bly by altering HDAC complexes rather than disrupting
them [35]. Third, we showed that the transcriptional pro-
file obtained by individual HDAC KD is not simply elab-
orated by inhibiting multiple HDAC enzymes but altered
altogether, and thus other mechanisms might contribute
to the HDACi effects other than targeting individual class
I HDAC enzymes. These differences might explain why
single class I HDAC KD is not as toxic as pan-inhibitory
HDACi treatment and fails to produce identical pheno-
typic effects, despite the probable effects of HDACi mainly
via class I HDAC enzymes.
Methods
Cell culture and drugs
Human cervix cancer cells HeLa, CCL-2 (American Type
Culture Collection, Manassas, VA) and mammary cancer
cells MCF-7 (HTB-22) were propagated in DMEM +
glutamax media supplemented with penicillin and strep-
tomycin and 10% FBS; the colon cancer cell line HCT116
(CCL-247) was maintained in RPMI-1640 media supple-
mented with glutamine, penicillin, streptomycin and
10% FBS (Invitrogen, Carlsbad, CA). All were grown in a
humidified atmosphere of 5% CO2 at 37°C and passaged
twice a week. Belinostat was synthesized as described in
recent patent applications (International publication
number US 6,888,027), and valproic acid was purchased
from Sigma-Aldrich (St. Louis, MO). Drugs were dissolved
in sterile water, aliquoted and stored at -20°C until use.
Transfection of siRNA
Pre-designed targeting siRNA SmartPOOL was purchased
from Dharmacon (Lafayette, CO) (non-targeting siRNA
D-001206-13, HDAC1 M-003493-02, HDAC2 M-
003495-01, HDAC3 M-003496-00). Cells were plated in
6-well plates, 250,000/well in complete media and incu-
bated overnight prior to aspiration of media and replace-
ment with OPTI-MEM (Invitrogen) with a final
concentration of 50 nM siRNA complexed with oligo-
fectamine (Invitrogen). Cells were incubated 4–6 hours
before addition of 1 ml growth medium with 20% FCS.
RNA extraction
Cells were plated in 6-well plates at 250,000/well and left
overnight before the transfection procedure, or replaced
with fresh media with drug at 0.5 μM for belinostat or 3.0
mM for VPA. 48 hours post-transfection and 24 hours
after drug treatment, total RNA was extracted with Trizol
according to the manufacturers protocol (Invitrogen). For
microarray samples, 5 of the 6 wells pr condition were
pooled to minimize well-to-well variation. The 6th well
was lysed directly in SDS sample buffer (Invitrogen), and
used for protein analysis.
DNA microarray analysis
RNA integrity was quality checked on the Agilent 2100
Bioanalyser (Agilent Technologies, Santa Clara, CA), then
processed and hybridized onto Affymetrix arrays accord-
ing to the manufacturer's protocol. Briefly, 5 μg RNA pr
sample was used to to generate biotin-labeled antisenseMolecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
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cRNA. After fragmentation, the labeled cRNA samples
were hybridized to Affymetrix HG-U133 Plus 2.0 arrays
(Affymetrix, Santa Clara, CA), washed and stained with
phycoerytrin conjugated streptavidin, and finally scanned
in the Affymetrix GeneArray® scanner to generate fluores-
cent images, as described in the Affymetrix GeneChip®
protocol. All statistical analyses, including pre-processing
of data was carried out in R, version 2.3 (R development
core team. R: A language and Environment for Statistical
Computing; http://www.R-project.org). DNA chips were
checked for quality assurance parameters such as visual
image inspection, replicate scatter plots and RNA degrada-
tion plots, before normalization for mean overall expres-
sion using the gcrma package (GC robust multiarray
algorithm) [36]. Agglomerative hierachical clustering
showed that the biological replicates clustered together as
expected (data not shown). The statistical linear model
based method of Limma (linear models for microarray
data package) [37] was found to be most sensitive at iden-
tifying genes with differential expression between control
and each condition. Raw p-values were adjusted for mul-
tiple testing using the Benjamini & Hochberg method [38]
to reduce the number of false positives, and a 5% signifi-
cance threshold applied. Comparisons of gene lists
between conditions was performed using VennMapper
[39].
Quantitative reverse transcription polymerase chain 
reaction
RNA was reverse transcribed by RT-PCR using 1 volume
diluted RNA (100 ng/μl) and 1 volume 2× RT-master mix
(High Capacity cDNA archive kit, Applied Biosystems,
Foster City, CA) exposed to 25°C 10 minutes and 37°C 2
hours. Samples were analyzed for gene-expression levels
by qRT-PCR, performed on ABI PRISM™ 7500 Sequence
Detection System (Applied Biosystems). Experiments
were done in triplicate by mixing 1 μL probe, 10 μL 2×
Taqman master mix and 9 μL cDNA diluted 1:50, and sub-
jecting samples to 40 cycles of amplification (15 seconds
denaturation at 95°C, 1 minute annealing and elongation
at 60°C), using GAPDH (HDAC KD) or β-Actin (drug
treatments) as endogenous controls. All pre-validated
FAM-labeled probes were purchased from Applied Biosys-
tems. Subsequent data analysis was performed using
DART-PCR version 1.0 [40].
Western Blotting
Cells were lysed directly in SDS sample buffer (Invitro-
gen) and electrophoretically separated and transferred to
nitrocellulose paper, following the manufacturer's
instructions (Invitrogen pre-cast Novex gels). Blots were
blocked in 10% non-fat skimmed milk, incubated over-
night with primary antibody, washed in Tris-buffered
saline with Tween-20 and visualized by HRP-conjugated
secondary antibodies (1:2,000) and ECL plus reagent (GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Antibodies uses were: rabbit anti-HDAC1 and -3 (1:1,000,
Cell Signaling Technology, Danvers, MA), mouse anti-
HDAC2 (1:10,000, Abcam, Cambridge, UK), rabbit anti-
Actin (1:5,000 Sigma-Aldrich).
CellTiter-Glo Assay
Scrambled control and HDAC KD cells were plated in trip-
licate at 10,000/well in 96-well format 24 hours post-
transfection. Cells were incubated 48 hours, without drug
for viability measurements, and within expected belinos-
tat toxicity limits for determination of IC50 values. Cells
were lysed directly with CellTiter-Glo luminescent viabil-
ity assay (Promega, Madison, WI), and luminescence pro-
portional to ATP present hence metabolically active cells
was measured (HTS 7000 plus Bioassay reader, Perk-
inElmer Life and Analytical Sciences, Waltham, MA). Data
were normalized to the scrambled control, and IC50 val-
ues determined in Prism 4 by generation of a sigmoidal
dose-response curve with variable slope (GraphPad Soft-
ware, San Diego, CA). Significant changes in mean viabil-
ity or IC50 values in the four groups (control, HDAC1, -2
or -3 KD) were calculated by ANOVA one-way analysis of
variance repeated measures test and Dunnett's multiple
comparisons test in Prism (GraphPad Software).
Caspase-Glo 3/7 assay
Cells were plated at 104/well, in quadroplicates for each
HDAC KD condition and control 48 hours post-transfec-
tion, or in triplicates for drug treatments. Plates were incu-
bated for 24 hours prior to direct lysis by Caspase-Glo 3/
7 reagent (Promega), and luminescence reading according
to caspase 3/7 activity.
Cell cycle analysis
Transfected cells were incubated for 48 hours before anal-
ysis. For drug treatments, cells were plated in 6-well for-
mat 2.5 × 105/well, incubated overnight, treated with drug
for 24 hours and processed as follows. Cells were perme-
abilized by incubation in ice-cold 70% ethanol, rehy-
drated in PBS supplemented with Tween-20 and FBS,
RNAse treated and DNA stained with propidium iodide.
Cells were analyzed using a FACSCalibur instrument and
the CellQuest software (BD Biosciences, Mountain View,
CA).
List of abbreviations
HDAC: histone deacetylase; HDACi: histone deacetylase
inhibitor; IC50: half maximal inhibitory concentration;
KD: knockdown; qRT-PCR: quantitative reverse tran-
scriptase polymerase chain reaction; siRNA: small interfer-
ing ribonucleic acid; TSA: trichostatin A; VPA: valproic
acid.Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
Page 11 of 12
(page number not for citation purposes)
Declaration of competing interests
Marielle Dejligbjerg was partly sponsored by a grant from
the Danish Ministry of Science, Technology and Innova-
tion, and the biotechnology company TopoTarget A/S.
Morten Grauslund is a shareholder and full-time
employee at TopoTarget A/S. Thomas Litman is an
employee of Exiqon A/S. Laura Collins is a previous
employee of TopoTarget A/S. Xiaozhong Qian and
Michael Jeffers are previous employees of CuraGen Corp.
Henri Lichenstein is a shareholder and full-time employee
at CuraGen Corp. Peter B Jensen is CEO of and share-
holder in TopoTarget A/S. Maxwell Sehested is CSO of and
shareholder in TopoTarget A/S.
Authors' contributions
MD designed and performed siRNA transfections, qRT-
PCR, western blotting, viability assays and flow cytometry
analyses, helped with secondary microarray analysis and
drafted the manuscript. MG participated in the design of
the study and drafting of the manuscript. TL and LC per-
formed microarray data analysis. XQ assisted in siRNA
transfections, western blotting and flow cytometry analy-
ses. MJ, HL, PBJ and MS conceived of the study, partici-
pated in its design and coordination, and provided
intellectual discussions and ideas regarding the content of
manuscript. All participating authors read and approved
the final manuscript.
Additional material
Acknowledgements
We thank Sanne Jul Christiansen, Mette Frandsen and Annette Nielsen for 
valuable technical skills, and Daniel Llorente Tabor for helping with IT (all 
are TopoTarget A/S employees).
References
1. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of his-
tone deacetylase inhibitors.  Nat Rev Drug Discov 2006, 5:769-784.
2. Gallinari P, DiMarco S, Jones P, Pallaoro M, Steinkuhler C: HDACs,
histone deacetylation and gene transcription: from molecu-
lar biology to cancer therapeutics.  Cell Res 2007, 17:195-211.
3. Strahl BD, Allis CD: The language of covalent histone modifica-
tions.  Nature 2000, 403:41-45.
4. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the
promise of epigenetic (and more) treatments for cancer.  Nat
Rev Cancer 2006, 6:38-51.
5. Bernstein BE, Tong JK, Schreiber SL: Genomewide studies of his-
tone deacetylase function in yeast.  Proc Natl Acad Sci USA 2000,
97:13708-13713.
6. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK: Role of
class I and class II histone deacetylases in carcinoma cells
using siRNA.  Biochem Biophys Res Commun 2003, 310:529-536.
7. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariada-
son JM, Rice VM: Drug-Induced Inactivation or Gene Silencing
of Class I Histone Deacetylases Suppresses Ovarian Cancer
Cell Growth: Implications for Therapy.  Cancer Biol Ther 2007,
6:795-801.
Additional file 1
Additional file A: Supplemental Figure 1. Validation of gene-expression 
changes from microarray analysis, by qRT-PCR. For each gene, data from 
microarray analysis and corresponding values from qRT-PCR analysis are 
included. Validation was shown for both one of the same RNA purifica-
tions as were used for microarray analysis ("A"), and independent ones in 
HeLa ("B"). A) Genes affected by HDACi treatment, B) Genes affected 
by HDAC KD
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-70-S1.doc]
Additional file 2
Additional file B: Supplemental Table A: Complete gene lists at ≥ 2-fold 
changes. Complete gene lists of significantly altered genes (5%) in all five 
conditions: HDAC 1, 2 or 3 KD, VPA or belinostat treatments, at 2-fold 
changes or more.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-70-S2.xls]
Additional file 3
Additional file C: Supplemental Table B: Transcriptional overlap 
between conditions. The overlapping proportion of genes regulated by one 
or more HDACi treatments and by one or more class I HDAC depletion, 
by at least 2-fold. Thus, these genes respond identically to both types of 
HDAC inhibition.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-70-S3.xls]
Additional file 4
Additional file D: Supplemental Figure 2. Effect of HDAC1, 2 and 1+2 
depletion using the siRNA technology in HeLa cells. A). Effect on cell pro-
liferation by measuring intracellular ATP levels. B) Effect on gene expres-
sion by measuring mRNA levels of selected genes by qRT-PCR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-70-S4.doc]
Additional file 5
Additional file E: Detailed comparison of microarray data from this 
study to the Senese et al. study [9]. The Power Point file contains 40 slides 
showing how the analysis was carried out and the results obtained herein
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-70-S5.ppt]
Additional file 6
Additional file F: Supplemental Table C: Combined analysis of the Sen-
ese and Dejligbjerg data. The Excel table allows direct comparison and 
sorting of the genes that were more than 1.5-fold differentially expressed 
following HDAC knockdown in the two studies.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-7-70-S6.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2008, 7:70 http://www.molecular-cancer.com/content/7/1/70
Page 12 of 12
(page number not for citation purposes)
8. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G,
Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C:
Essential function of histone deacetylase 1 in proliferation
control and CDK inhibitor repression.  EMBO J 2002,
21:2672-2681.
9. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A,
Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S: A role for
histone deacetylase 1 in human tumor cell proliferation.  Mol
Cell Biol 2007, 27:4784-4795.
10. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju
GC, Hooi SC: Inhibition of histone deacetylase 2 increases
apoptosis and p21Cip1/WAF1 expression, independent of
histone deacetylase 1.  Cell Death Differ 2005, 12:395-404.
11. Zhu P, Huber E, Kiefer F, Gottlicher M: Specific and redundant
functions of histone deacetylases in regulation of cell cycle
and apoptosis.  Cell Cycle 2004, 3:1240-1242.
12. Waltregny D, Glenisson W, Tran SL, North BJ, Verdin E, Colige A,
Castronovo V: Histone deacetylase HDAC8 associates with
smooth muscle alpha-actin and is essential for smooth mus-
cle cell contractility.  FASEB J 2005, 19:966-968.
13. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni
D, Chakravarty P, Paolini C, De FR, Gallinari P, Steinkuhler C, DiMa-
rco S: Crystal structure of a eukaryotic zinc-dependent his-
tone deacetylase, human HDAC8, complexed with a
hydroxamic acid inhibitor.  Proc Natl Acad Sci USA 2004,
101:15064-15069.
14. Verdin E, Dequiedt F, Kasler HG: Class II histone deacetylases:
versatile regulators.  Trends Genet 2003, 19:286-293.
15. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL:
Domain-selective small-molecule inhibitor of histone
deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Proc Natl Acad Sci USA 2003, 100:4389-4394.
16. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY:
Expression profile of histone deacetylase 1 in gastric cancer
tissues.  Jpn J Cancer Res 2001, 92:1300-1304.
17. Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, Tan-
zawa H: Aberrant expression of histone deacetylase 6 in oral
squamous cell carcinoma.  Int J Oncol 2006, 29:117-124.
18. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai
I, Yamakawa Y, Fujii Y: Histone deacetylase 1 mRNA expression
in lung cancer.  Lung Cancer 2004, 46:171-178.
19. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y,
Arango D, Velcich A, Augenlicht LH, Mariadason JM: Histone
deacetylase 3 (HDAC3) and other class I HDACs regulate
colon cell maturation and p21 expression and are deregu-
lated in human colon cancer.  J Biol Chem 2006,
281:13548-13558.
20. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita
K, Hamaguchi M, Hayashi S, Iwase H: HDAC6 expression is cor-
related with better survival in breast cancer.  Clin Cancer Res
2004, 10:6962-6968.
21. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M:
Induction of HDAC2 expression upon loss of APC in colorec-
tal tumorigenesis.  Cancer Cell 2004, 5:455-463.
22. Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T,
Wurst W, Minucci S, Gottlicher M: Reduced body size and
decreased intestinal tumor rates in HDAC2-mutant mice.
Cancer Res 2007, 67:9047-9054.
23. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J,
Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-
Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris
MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: Loss of
acetylation at Lys16 and trimethylation at Lys20 of histone
H4 is a common hallmark of human cancer.  Nat Genet 2005,
37:391-400.
24. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK:
Gene expression profiling of multiple histone deacetylase
(HDAC) inhibitors: defining a common gene set produced by
HDAC inhibition in T24 and MDA carcinoma cell lines.  Mol
Cancer Ther 2003, 2:151-163.
25. Gray SG, Qian CN, Furge K, Guo X, Teh BT: Microarray profiling
of the effects of histone deacetylase inhibitors on gene
expression in cancer cell lines.  Int J Oncol 2004, 24:773-795.
26. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian
X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A,
Ritchie JW, Jensen PB, Lichenstein HS, Sehested M: Determination
of the class and isoform selectivity of small molecule HDAC
inhibitors.  Biochem J 2007, 409:581-589.
27. Glaser KB: HDAC inhibitors: Clinical update and mechanism-
based potential.  Biochem Pharmacol 2007, 74:659-671.
28. Takami Y, Nakayama T: N-terminal region, C-terminal region,
nuclear export signal, and deacetylation activity of histone
deacetylase-3 are essential for the viability of the DT40
chicken B cell line.  J Biol Chem 2000, 275:16191-16201.
29. de Ruijter AJ, Meinsma RJ, Bosma P, Kemp S, Caron HN, van Kuilen-
burg AB: Gene expression profiling in response to the histone
deacetylase inhibitor BL1521 in neuroblastoma.  Exp Cell Res
2005, 309:451-467.
30. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M,
Scarpa A: Gene expression profiling after treatment with the
histone deacetylase inhibitor trichostatin A reveals altered
expression of both pro- and anti-apoptotic genes in pancre-
atic adenocarcinoma cells.  Biochim Biophys Acta 2004,
1693:167-176.
31. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA,
Holloway AJ, Johnstone RW: Identification and functional signif-
icance of genes regulated by structurally different histone
deacetylase inhibitors.  Proc Natl Acad Sci USA 2005,
102:3697-3702.
32. Whetstine JR, Ceron J, Ladd B, Dufourcq P, Reinke V, Shi Y: Regula-
tion of tissue-specific and extracellular matrix-related genes
by a class I histone deacetylase.  Mol Cell 2005, 18:483-490.
33. Zupkovitz G, Tischler J, Posch M, Sadzak I, Ramsauer K, Egger G,
Grausenburger R, Schweifer N, Chiocca S, Decker T, Seiser C: Neg-
ative and positive regulation of gene expression by mouse
histone deacetylase 1.  Mol Cell Biol 2006, 26:7913-7928.
34. Foglietti C, Filocamo G, Cundari E, De RE, Lahm A, Cortese R,
Steinkuhler C: Dissecting the biological functions of Dro-
sophila histone deacetylases by RNA interference and tran-
scriptional profiling.  J Biol Chem 2006, 281:17968-17976.
35. Mottus R, Sobel RE, Grigliatti TA: Mutational analysis of a histone
deacetylase in Drosophila melanogaster: missense muta-
tions suppress gene silencing associated with position effect
variegation.  Genetics 2000, 154:657-668.
36. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F: A Model
Based Background Adjustment for Oligonucleotide Expres-
sion Arrays.  Technical Report, John Hopkins University, Department of
Biostatistics Working Papers 2003.
37. Smyth GK: Linear models and empirical bayes methods for
assessing differential expression in microarray experiments.
Stat Appl Genet Mol Biol 2004, 3:. Article 3
38. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a
practical and powerful approach to multiple testing.  J R Statist
Soc B 1995, 57:289-300.
39. Smid M, Dorssers LC, Jenster G: Venn Mapping: clustering of
heterologous microarray data based on the number of co-
occurring differentially expressed genes.  Bioinformatics 2003,
19:2065-2071.
40. Peirson SN, Butler JN, Foster RG: Experimental validation of
novel and conventional approaches to quantitative real-time
PCR data analysis.  Nucleic Acids Res 2003, 31:e73.
41. Simon RM, Korn EL, McShane LM, Radmacher MD, Wright GW,
Zhao Y: Design and analysis of DNA microarray investiga-
tions.  New York: Springer; 2003. 